logo
logo
The Oncology Institute, Inc.

The Oncology Institute, Inc.

NASDAQ•TOI
CEO: Mr. Richard Alan Barasch
セクター: Healthcare
業種: Medical - Care Facilities
上場日: 2020-06-04
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
連絡先情報
18000 Studebaker Road, Suite 800, Cerritos, CA, 90703, United States
562-735-3226
theoncologyinstitute.com
時価総額
$246.94M
PER (TTM)
-36.9
33.4
配当利回り
--
52週高値
$4.88
52週安値
$0.60
52週レンジ
45%
順位48Top 64.4%
3.3
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
弱い • 3.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$136.56M+36.70%
直近4四半期の推移

EPS

-$0.14-22.22%
直近4四半期の推移

フリーCF

-$13.23M-1183.87%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Total Revenue Growth Total operating revenue reached $360.8M (9M 2025), reflecting 23.1% growth compared to $293.1M in the prior year period.
Dispensary Revenue Surge Dispensary revenue grew 41.9% to $187.8M (9M 2025), driven by a significant increase in prescription fills across the network.
SG&A Expense Reduction Selling, general, administrative expense totaled $77.5M (9M 2025), decreasing 6.6% due to cost discipline and operational efficiency measures.
Net Loss Per Share Improvement Net loss per share improved to $(0.49) diluted for nine months ended September 30, 2025, versus $(0.56) in the comparable prior period.

リスク要因

Equity Deficit Widening Stockholders' equity deficit worsened to $(12.3)M as of September 30, 2025, compared to $(3.6)M recorded at December 31, 2024.
Cash Position Decline Cash equivalents decreased 42% to $27.7M at period end, despite recent capital raises and financing activities completed.
Segment Restructuring Loss Recognized a $2.4M loss due to the write-off of net assets related to the Clinical Trials segment restructuring effective May 2025.
High Vendor Concentration Significant vendor concentration risk noted, with Vendor A comprising 99% of Direct Costs for the third quarter of 2025.

見通し

Sufficient Liquidity Confirmed Management concluded liquidity is sufficient to fund operations for at least one year from the date these consolidated financial statements are issued.
Cash Burn Elimination Focus Strategic priority focused on eliminating cash burn via working capital management and achieving a 5% SG&A reduction versus prior year.
AI Technology Pilots Planned Planning launch of AI pilots for prior-authorization and denial automation during the fourth quarter of 2025 to drive further leverage.
Recent Private Placement Funding Secured approximately $16.5M gross proceeds from the March 24, 2025 private placement offering before deducting associated fees.

同業比較

売上高 (TTM)

Community Health Systems, Inc.CYH
$12.64B
+0.7%
agilon health, inc.AGL
$5.89B
+9.9%
Cross Country Healthcare, Inc.CCRN
$1.13B
-22.1%

粗利益率 (最新四半期)

Semler Scientific, Inc.SMLR
91.5%
+0.1pp
Treace Medical Concepts, Inc.TMCI
79.1%
-1.1pp
OrthoPediatrics Corp.KIDS
73.9%
+0.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
SNDA$640.61M-13.3-44.1%80.1%
TALK$631.35M149.73.7%0.0%
DSGN$573.63M-8.5-30.6%0.8%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
10.8%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月23日
|
EPS:-$0.08
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月13日|
    売上高: $136.56M+36.7%
    |
    EPS: $-0.14-22.2%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月13日|
    売上高: $119.80M+21.5%
    |
    EPS: $-0.15-11.8%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月14日|
    売上高: $104.41M+10.3%
    |
    EPS: $-0.21-4.5%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月26日|
    売上高: $393.41M+21.3%
    |
    EPS: $-0.71+22.8%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月13日|
    売上高: $99.90M+21.8%
    |
    EPS: $-0.18-5.3%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月13日|
    売上高: $98.58M+22.9%
    |
    EPS: $-0.17-26.1%
    予想を下回る

  • Form 10-Q/A - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月22日|
    売上高: $94.67M+24.2%
    |
    EPS: $-0.22-46.3%
    予想を下回る

  • Form 10-K/A - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年5月22日|
    売上高: $324.24M+28.4%
    |
    EPS: $-0.92-102322.2%
    予想を下回る